Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Group and Ascenta Therapeutics have partnered to develop and commercialize AT-406 (called Debio 1143 by Debiopharm).
Subscribe to our email newsletter
AT-406 is an orally available small molecule helps in neutralizing major inhibitors of apoptosis and is anticipated to be effective in treating cancers in conjunction with anti-cancer therapies.
AT-406 can induce cancer cell death and/or potentiate the efficacy of other treatments.
Debiopharm President and Founder Rolland-Yves Mauvernay said it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring benefits to patients by enhancing the efficiency of the treatment.